{
 "id": "chronic-obstructive-pulmonary-disease",
 "name": "Chronic obstructive pulmonary disease",
 "aliases": [
  "Chronic Obstructive Pulmonary Disease",
  "Chronic obstructive pulmonary disease (COPD)"
 ],
 "acronyms": [
  "COPD"
 ],
 "bodySystem": "respiratory",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 3
 },
 "funds": [
  {
   "fund": "Chronic Obstructive Pulmonary Disease - Medicare Access",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Chronic obstructive pulmonary disease (COPD)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 3500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "fund": "Chronic obstructive pulmonary disease (COPD) health equity",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 3500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "Ipratropium Bromide",
   "pages": [
    {
     "brand": "Atrovent HFA",
     "url": "https://omnirx.org/medicines/atrovent-hfa"
    }
   ],
   "labelSentence": "ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22170e98ef-5560-4068-be7d-e649068eb884%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Ipratropium/Albuterol Sulfate",
   "pages": [
    {
     "brand": "Combivent Respimat",
     "url": "https://omnirx.org/medicines/combivent-respimat"
    }
   ],
   "labelSentence": "(an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%229832312e-0310-4ab6-8501-afa976fc7eb2%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Mepolizumab",
   "pages": [
    {
     "brand": "Nucala",
     "url": "https://omnirx.org/medicines/nucala"
    }
   ],
   "labelSentence": "Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22fefb887c-e4ac-431e-8893-e9d1a5a63fea%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Asthma Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/asthma-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "GSK Patient Assistance Program (GSK ViiV Healthcare Patient Access Programs Foundation)",
     "url": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "List of eligible products (GSK prescription medicines)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tiotropium Bromide",
   "pages": [
    {
     "brand": "Spiriva Respimat",
     "url": "https://omnirx.org/medicines/spiriva-respimat"
    },
    {
     "brand": "Spiriva Handihaler",
     "url": "https://omnirx.org/medicines/spiriva-handihaler"
    }
   ],
   "labelSentence": "SPIRIVA HANDIHALER (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22820839ef-e53d-47e8-a3b9-d911ff92e6a9%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Umeclidinium Bromide",
   "pages": [
    {
     "brand": "Incruse Ellipta",
     "url": "https://omnirx.org/medicines/incruse-ellipta"
    }
   ],
   "labelSentence": "Umeclidinium ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22763388a5-cc89-4c25-8562-521df679b7e8%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "GSK Patient Assistance Program (GSK ViiV Healthcare Patient Access Programs Foundation)",
     "url": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "List of eligible products (GSK prescription medicines)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Budesonide/Formoterol Fumarate",
   "pages": [],
   "labelSentence": "Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220ce4cd21-ac96-4b39-9e1c-49f86c87fa1a%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}